Objective
Important vaccine against human pathogens, e.g. poliomyelitis virus and hepatitis B virus, could only be developed by trials in non-human primates. BSL 2 or 3 facilities suitable for housing infected non-human primates are scarce in Europe. No single European institute can house sufficient animals to generate statistically reliable results comparing multiple vaccine strategies. Thus, eight European primate facilities will establish a network for preclinical vaccine evaluation in non-human primates. To contribute to AIDS vaccine development and to prove our capacity to conduct highly co-ordinated vaccine trials, we propose to optimise combination of three genetically- based vaccines in a multi-centre experiment. Our concerted approach will optimise scarce European resources, improve our ability to conduct preclinical vaccine trials in relevant challenge models and enhance the global competitiveness of European vaccine developers.
Fields of science
- natural sciencesbiological scienceszoologymammalogyprimatology
- medical and health sciencesbasic medicineimmunologyimmunisation
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
37077 Göttingen
Germany
See on map
Participants (7)
75015 Paris
See on map
2288 GJ Rijswijk Zh
See on map
00161 Rome
See on map
SP4 0JG Salisbury
See on map
Potters Bar
See on map
63225 Langen
See on map
Solna
See on map